All cases of 46,XY DSD (except for two homozygous mutations) are heterozygous for the mutation, indicating that SF-1 dosage is critical.8,9 The varying locations of the different NR5A1 mutations suggest the absence of a mutation hot spot and the lack of a founder effect. This evidence concerns the gene NR5A1 and disorder of sexual differentiation.